Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma

INTRODUCTION: This subgroup analysis of the LYM-3002 Phase III study (NCT00722137) investigated whether substituting bortezomib for vincristine in frontline R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy could improve outcomes in East Asian patients with n...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Jie, Okamoto, Rumiko, Yoon, Sung-Soo, Shih, Lee-Yung, Zhu, Jun, Liu, Ting, Hong, Xiaonan, Pei, Lixia, Rooney, Brendan, van de Velde, Helgi, Huang, Huiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039072/
https://www.ncbi.nlm.nih.gov/pubmed/30013367
http://dx.doi.org/10.2147/OTT.S150339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039072/
https://www.ncbi.nlm.nih.gov/pubmed/30013367
http://dx.doi.org/10.2147/OTT.S150339

Ejemplares similares